Science & academia

This archive covers milestones and breakthroughs from the scientific and academic world — researchers, universities, and institutions whose work advances human knowledge. Stories here highlight discoveries, studies, and scholarly efforts that point toward a better future.

Chimp in a tree, for article on carbon financing biodiversity

Birdsong and chimp drumming suggest carbon financing is helping Sierra Leone’s forest

By / / Good News For Humankind

Carbon financing in Sierra Leone’s Gola Rainforest is doing more than locking away carbon — it’s bringing the forest back to life, according to a new study in Conservation Science and Practice. Researchers recorded audio at 133 sites and found the protected park’s dawn chorus was measurably richer than the community forest right next door, with the shift happening sharply at the border. The idea, drawn from the acoustic niche hypothesis, is that more species means more sound frequencies filled, like instruments in an orchestra each holding a lane. It’s one of the first direct signs that REDD+ programs, long sold on climate grounds, may genuinely shelter biodiversity too — a hopeful nudge for how the world funds living forests everywhere.

Depiction of DNA, for article on gene therapy for inherited deafness

U.S. FDA approves first-ever gene therapy for inherited deafness, free to patients

By / / Good News For Humankind

The FDA has approved the first-ever gene therapy for inherited deafness. In its 20-child trial, 16 saw their hearing improve within months — and some could make out whispers for the first time.
Called Otarmeni, the one-time treatment uses two harmless viruses to deliver working copies of the OTOF gene deep into the inner ear, restoring otoferlin, the protein the cochlea needs to turn sound into signals the brain can read. Its maker, Regeneron, says it will offer the therapy free to patients in the U.S. Doctors who ran the trial described children responding to their parents’ voices, and to music, for the first time.
This particular genetic form of deafness is rare, affecting roughly 50 babies born in the U.S. each year. But researchers believe the breakthrough cracks open the door to gene therapies for many other inherited conditions worldwide.

Professional office, for article on four-day work week

Four-day week cut burnout without cutting output, Australian study finds

By / / Good News For Humankind

Four-day work weeks held up beautifully in a two-year Australian trial just published in a Nature Portfolio journal — 14 of the 15 companies involved decided to keep the shorter week for good. Six actually saw productivity rise, and the rest held steady. The secret wasn’t cramming five days into four, but rethinking the work itself: cutting pointless meetings, automating repetitive tasks, and letting people focus on what mattered. Six of the companies said their main motivation was easing burnout, which a 2025 Beyond Blue survey found affects one in two Australian workers. As AI reshapes what humans actually need to do at work, this quiet experiment suggests a hopeful answer to where those reclaimed hours could go — back to us.

Cancer patient reading a book, for article on pre-surgery immunotherapy

Bowel cancer patients see zero relapses three years after new immunotherapy

By / / Good News For Humankind

Bowel cancer patients in a small U.K. trial saw zero relapses nearly three years after receiving immunotherapy before surgery — a striking result for all 32 participants, even those who still had traces of cancer after treatment. By comparison, the standard path of surgery followed by chemotherapy sees roughly one in four patients relapse within three years. The trial focused on people with a specific genetic profile that makes tumors more visible to the immune system, sparing them months of post-surgery chemo. One participant described the cancer “melting away” before his operation. If larger trials confirm the approach, it could reshape how a meaningful slice of bowel cancer cases are treated worldwide.

Infant feet, for article on nirsevimab RSV infant hospitalizations

Spanish study links RSV antibody to 86% drop in infant hospitalizations

By / / Good News For Humankind

Nirsevimab, a long-acting antibody given to every infant in one Spanish region, cut RSV hospitalizations by 86% compared to previous seasons, according to a new study out of Valladolid University. Babies under six months — the group hit hardest by RSV every winter — saw the biggest drop, with pediatric intensive care admissions falling sharply too. Unlike a traditional vaccine, the shot delivers ready-made antibodies directly, which matters for newborns whose immune systems are still developing. Several European countries and the U.S. have already added it to routine infant care, and early data abroad echo the Spanish results. The remaining challenge is making sure families in lower-income countries, where RSV hits hardest, aren’t left waiting.

University of Chicago campus, for article on University of Chicago free tuition

University of Chicago expands free tuition to families earning under $250k

By / / Good News For Humankind

Free tuition at the University of Chicago will soon reach families earning up to $250,000 a year — a ceiling roughly two to three times higher than most peer programs. Starting in autumn 2027, qualifying students pay nothing toward tuition, and those from households under $125,000 also get room, board, and fees covered. The move directly addresses the middle-income squeeze, where families often earn too much for traditional aid but too little to absorb a tuition bill north of $65,000 without serious debt. UChicago says it will also simplify the aid process itself, which trips up many families. As elite universities face growing pressure on access, commitments like this one reshape what affordability can look like at the top of American higher education.

Two sets of hand holding newborn baby, for article on Coartem Baby malaria treatment

W.H.O. approves world’s first malaria treatment for newborn babies

By / / Good News For Humankind

Newborn babies with malaria finally have a medicine made just for them. Coartem Baby, a cherry-flavored tablet that dissolves into breast milk or water, just earned World Health Organization prequalification — a green light that opens the door to public health systems across sub-Saharan Africa. For decades, doctors had to guess at doses using drugs built for older children, even as research showed infants were getting infected too. Ghana has already begun rolling it out, and Novartis has committed to what it calls “largely not-for-profit pricing” in malaria-endemic regions. Alongside new vaccines and better bed nets, it’s a quiet but meaningful sign that the fight against malaria — which still kills hundreds of thousands of children a year — is reaching the patients it had long overlooked.

Little Free Pantry, for article on little free pantry app

University of Washington researchers map little free pantries with new app

By / / Good News For Humankind

Little free pantries across Seattle quietly move an estimated 4 million pounds of food a year — more than the state’s largest food bank — and a new University of Washington app called PantryMap is helping that grassroots web run smarter. Users can check stock levels, post wish lists, and log donations in real time, while four pilot pantries now use privacy-preserving sensors that track weight and door activity without any cameras. Volunteers are already putting it to work, recently distributing 25,000 pounds of donated food to micropantries by bicycle. It’s a hopeful glimpse of how neighbor-to-neighbor sharing, paired with thoughtful technology, can tackle hunger and food waste together — one cupboard at a time.

Holding a nasal spray, for article on prehospital stroke nasal spray

Hong Kong researchers develop world-first nasal spray for stroke, cutting damage 80%

By / / Good News For Humankind

A nasal spray for stroke, developed at the University of Hong Kong, cut brain damage by more than 80% when given within 30 minutes of an ischemic stroke in preclinical studies. The idea is beautifully simple: tiny particles travel from the nose directly along nerve pathways to the brain, sidestepping the blood-brain barrier that derails most neurological drugs. Designed to be as easy to use as an EpiPen, it could let a bystander start protecting brain cells before the ambulance even arrives. Clinical trials are still years away, but if it holds up, this kind of “protection-first” thinking could reshape emergency care for stroke patients everywhere — especially the 85% who currently never reach treatment in time.

Supplement capsule, for article on vitamin D breast cancer study

Brazilian scientists find that vitamin D boosts breast cancer treatment success by 79%

By / / Good News For Humankind

Vitamin D may give breast cancer chemotherapy a meaningful boost, according to a new randomized trial in Brazil. Among 80 women undergoing chemo before surgery, those taking 2,000 IU of vitamin D daily saw their tumors completely disappear 43% of the time, compared with 24% in the placebo group. Researchers think the nutrient may act as a chemosensitizer, helping cancer cells respond more fully to treatment. The authors are careful to note that a trial this small isn’t the final word, and larger studies are needed before guidelines change. Still, the idea that something as simple, safe, and affordable as vitamin D could improve outcomes for the world’s most commonly diagnosed cancer is genuinely hopeful news worth watching.